Skip to main content
. 2004 Apr;48(4):1384–1396. doi: 10.1128/AAC.48.4.1384-1396.2004

FIG. 1.

FIG. 1.

MIC distributions of doripenem, ertapenem, imipenem, and meropenem against 211 isolates of ESBL-negative or ceftazidime-susceptible Enterobacteriaceae (A) and 140 isolates of ESBL-positive or ceftazidime-intermediate or ceftazidime-resistant Enterobacteriaceae (B).